Real-life Experience in Brazil in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+Abiraterone
NCT06457854 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2025-03-12
Summary
PROCeed is an observational study assessing real world clinical endpoints and demographic characteristics in patients with castration-resistant prostate cancer treated with Olaparib+Abiraterone.
Conditions
- Prostatic Neoplasms
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Henrique Helber · Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein Centro de Ensino e Pesquisa Albert Einstein
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-01-01
- Primary Completion
- 2025-02-04
- Completion
- 2025-02-04
Countries
- Brazil
Study Locations
More Related Trials
-
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
NCT02217566 ·Status: COMPLETED ·Phase: PHASE2
-
Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
NCT03516812 ·Status: COMPLETED ·Phase: PHASE2
-
Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy
NCT02121639 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer
NCT02789878 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650 ·Status: RECRUITING ·Phase: PHASE3
-
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
NCT03012321 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer
NCT02064608 ·Status: COMPLETED ·Phase: PHASE1
-
Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer
NCT02254785 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
NCT01845792 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
NCT01313273 ·Status: TERMINATED ·Phase: PHASE3
-
Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome
NCT04622761 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.
NCT02036060 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
NCT05498272 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer
NCT02066961 ·Status: COMPLETED
-
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624 ·Status: RECRUITING ·Phase: PHASE3
-
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
NCT06783127 ·Status: RECRUITING
-
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
NCT01309672 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
NCT02003924 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone Acetate
NCT01858441 ·Status: COMPLETED ·Phase: NA
-
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
NCT00924469 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
NCT02987543 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
NCT00846976 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer
NCT01637402 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
NCT01734681 ·Status: WITHDRAWN ·Phase: PHASE2
-
Abiraterone Acetate for Castrate Resistant Prostate Cancer
NCT01961843 ·Status: COMPLETED ·Phase: NA